Do CVID patients on SCIG have more autoimmune (thrombo)cytopenic events than CVID patients on IVIG?
Nadezhda Camacho-Ordonez, Aleksandra Hirsch, Luiza Campos, Sigune Goldacker, Siobhan O. Burns, Fernando Moreira, Klaus Warnatz, Bodo Grimbacher · 2025
Read Do CVID patients on SCIG have more autoimmune (thrombo)cytopenic events than CVID patients on IVIG? by Nadezhda Camacho-Ordonez, Aleksandra Hirsch, Luiza Campos, Sigune Goldacker, Siobhan O. Burns, Fernando Moreira, Klaus Warnatz, Bodo Grimbacher (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12695766.txt.
Description
Autoimmune thrombocytopenia (AITP) is frequent in patients diagnosed with common variable immunodeficiency (CVID). High dose intravenous immunoglobulin treatment (IVIG) has conventionally been a cornerstone of the initial therapy for AITP. This study aimed to assess the safety and effectiveness of subcutaneous immunoglobulin (SCIG) compared to IVIG in preventing AITP in CVID patients.
Catalog record
| CREATOR | Nadezhda Camacho-Ordonez, Aleksandra Hirsch, Luiza Campos, Sigune Goldacker, Siobhan O. Burns, Fernando Moreira, Klaus Warnatz, Bodo Grimbacher |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |